Select Page
Cerus Websites
Cerus.com
The corporate website includes broad information about Cerus, resources for investors, and career opportunities.INTERCEPT-USA.com
For residents of the United States – Blood centers and transfusion services will find topics related to the production of INTERCEPT pathogen reduced platelet and plasma products.HCP.INTERCEPT-USA.com
For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education for platelet and plasma products.INTERCEPT-Canada.com
For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.INTERCEPTBloodSystem.com
Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.INTERCEPT-Cryoprecipitation.com
For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.
INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:
INDICATIONS FOR USE
• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
• Second-line therapy for von Willebrand disease (vWD).
• Control of uremic bleeding after other treatment modalities have failed.
Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.
CONTRAINDICATIONS
Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.
Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.
WARNINGS AND PRECAUTIONS
Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.
For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.
By continuing to use this website, you agree to the use of cookies described in our Cookies Policy.